Changes in Body Composition Secondary to Neoadjuvant Chemotherapy for Advanced Esophageal Cancer are Related to the Occurrence of Postoperative Complications After Esophagectomy
- 722 Downloads
Although a survival benefit of neoadjuvant treatment for patients with esophageal cancer has been highlighted, the influence of neoadjuvant treatment on the nutritional status of patients with esophageal cancer is not well understood.
Changes in body composition parameters were assessed in 30 patients who underwent neoadjuvant chemotherapy (NAC) comprising docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy from August 2009 to April 2013. Body composition was evaluated before and after NAC using multifrequency bioelectrical impedance analysis (InBody 720; Biospace, Tokyo, Japan). Postoperative complications were graded according to the Clavien-Dindo classification.
Twenty-three postoperative events occurred in 16 patients. A decrease in body protein was observed in 13 patients (43.3 %), while skeletal muscle (SM), body cell mass (BCM), and fat-free mass (FFM) declined in 11 patients (36.7 %) during NAC. Changes in these four parameters during chemotherapy significantly differed between patients with postoperative complications and those without: protein, −1.6 ± 0.9 versus +4.4 ± 2.1 kg (P = 0.01); SM, −1.3 ± 1.1 versus +4.7 ± 2.4 kg (P = 0.02); BCM, −2.4 ± 1.6 versus +3.8 ± 2.2 kg (P = 0.03); and FFM, −1.4 ± 1.4 versus +4.3 ± 2.3 kg (P = 0.04).
Changes in body composition parameters are possible predictive markers of postoperative complications after esophagectomy after NAC. Further analysis is needed to clarify whether nutritional intervention improves such parameters and thus contributes to reduced postoperative morbidity.
KeywordsPostoperative Complication Docetaxel Body Composition Esophageal Cancer Esophageal Squamous Cell Carcinoma
The authors report no financial interests or potential conflicts of interest.
- 4.Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.PubMedCrossRefGoogle Scholar
- 7.Yoshida N, Watanabe M, Baba Y, et al. Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer. Dis Esophagus. 2014;27:374–9.Google Scholar
- 11.Sobin LH, Gospodarowicz MK, Wittekind CW. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.Google Scholar
- 19.Jackson W, Alexander N, Schipper M, Fig L, Feng F, Jolly S. Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy X-ray absorptiometry (DEXA). Head Neck. 2013. doi: 10.1002/hed.23461.